Loading clinical trials...
Loading clinical trials...
Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 Following Administration of SEL-110) in Pediatric Subjects With Mut Subtype Isolated Methylmalonic Acidemia (MMA)
Conditions
Interventions
SEL-302
Locations
1
United States
National Human Genome Research Institute, National Institutes of Health
Bethesda, Maryland, United States
Start Date
December 19, 2022
Primary Completion Date
August 1, 2025
Completion Date
August 1, 2029
Last Updated
September 24, 2024
Lead Sponsor
Selecta Biosciences, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions